Newsletter Tool

Today’s Big News

Nov 6, 2024

Novo Nordisk discards kidney disease drug from $1.3B deal in wake of phase 3 fail

ASH: New Gilead-Arcellx data build CAR-T’s case against Carvykti in advanced multiple myeloma

More M&A, or a shake-up at the FDA? Pharma braces for Trump's return to the White House

MacroGenics pauses work on vobra duo ADC pending mature survival data

Tango has last dance with PRMT5 inhibitor, pirouettes into embrace with 2 sibling molecules

Ring Therapeutics calls on Singapore research agencies for gene therapy R&D partnership

Acadia to make $100M profit from selling pediatric review voucher for $150M

Featured

Novo Nordisk discards kidney disease drug from $1.3B deal in wake of phase 3 fail

By James Waldron

Novo Nordisk, after mulling the implications of a phase 3 fail, has given up on a late-stage kidney drug acquired in a $1.3 billion deal.

ASH: New Gilead-Arcellx data build CAR-T's case against Carvykti in advanced multiple myeloma

By Gabrielle Masson

Arcellx has shared several data cuts on anito-cel, a CAR-T being developed with Gilead’s Kite Pharma to treat relapsed or refractory multiple myeloma. After seeing the data, analysts underscored the therapy’s best-in-class potential compared to Johnson & Johnson and Legend Biotech's FDA-approved treatment Carvykti.

More M&A, or a shake-up at the FDA? Pharma braces for Trump's return to the White House

By Zoey Becker

Over his first term, Donald Trump advocated for lower drug prices and pharmacy benefit manager reform. Now with the Inflation Reduction Act in play, what's to come for pharma under a Trump administration?

Overcoming Barriers to Generative AI in Life Sciences R&D

MacroGenics pauses work on vobra duo ADC pending mature survival data

By Nick Paul Taylor

MacroGenics has pumped the brakes on vobra duo, pausing investment in additional opportunities for the antibody-drug conjugate until it has updated data from a phase 2 monotherapy prostate cancer trial.

Tango has last dance with PRMT5 inhibitor, pirouettes into embrace with 2 sibling molecules

By Nick Paul Taylor

Tango Therapeutics has shuffled TNG908 off the dance floor, halting enrollment in a study of the cancer drug candidate to focus its resources on two other molecules that hit the same target. Shares in Tango fell 26% to $3.81 in premarket trading.

Ring Therapeutics calls on Singapore research agencies for gene therapy R&D partnership

By Darren Incorvaia

Ring Therapeutics is calling on Singaporean research agencies to dial into a new collaboration to develop gene therapies for eye diseases and cancer.

Acadia to make $100M profit from selling pediatric review voucher for $150M

By James Waldron

Acadia Pharmaceuticals has bagged $150 million from the sale of a priority review voucher—although the biotech will only be able to keep two-thirds of the windfall.

Medidata meshes services into bundles for oncology and vaccine clinical trials

By Darren Incorvaia

Medidata has debuted two new bundled services meant to speed up and support clinical trials in oncology and vaccines, the company announced Oct. 31.

UPDATED: AstraZeneca stock tanks over fears of expanding China fraud probe

By Angus Liu

AstraZeneca’s stock price dropped by 8.4% during Tuesday’s trading in London after a report fueled fears of a potentially escalating insurance fraud investigation in China.

Fierce podcasts

Don’t miss an episode

Drug pricing and the 2024 presidential election

This week on "The Top Line," we explore how each presidential candidate’s approach to drug pricing could shape future policy.

Best practices for health system-startup partnerships

The pulse of the medtech industry

Resources

Whitepaper

Single Cell RNA Profiling FFPE Tissue

Explore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence.

7 “Make or Break” Factors for Emerging Biopharma Companies

This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development.

Intensified Biomanufacturing

Unlock the secrets to faster, cost-effective biologics production with intensified biomanufacturing – download the whitepaper and power up your bioprocessing game!

Sponsored by: Syngene International Ltd.

Whitepaper

Is That Heart Attack Really an Adverse Event?

Discover how independent adjudication can safeguard your clinical trials from misidentified adverse events and enhance the credibility of your results.

Planning for success in cell-based manufacturing

Learn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes.

Presented by: Thermo Fisher Scientific